Core Viewpoint - A securities class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making false and misleading statements regarding its manufacturing processes and the prospects of its products, particularly briquilimab [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of individuals or entities that purchased Jasper securities between November 30, 2023, and July 3, 2025 [1]. - The complaint alleges that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results [2]. Group 2: Allegations Against the Company - The failure to ensure compliance with manufacturing regulations increased the risk of confounding study results, adversely affecting the regulatory and commercial prospects of Jasper's products [2]. - The allegations suggest that the company's business and financial prospects, as well as the clinical and commercial prospects of briquilimab, were overstated [2]. - As a result of these issues, the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 3: Investor Information - Investors who acquired shares of Jasper are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on November 18, 2025 [3].

Group 1 - The law firm Faruqi & Faruqi, LLP is investigating potential claims against Semler Scientific, Inc. and has set a deadline of October 28, 2025, for investors to seek the role of lead plaintiff in a federal securities class action [2][4] - The complaint alleges that Semler Scientific and its executives violated federal securities laws by making false or misleading statements and failing to disclose a material investigation by the U.S. Department of Justice regarding violations of the False Claims Act [4][5] - Following the disclosure of initial settlement discussions with the DOJ, Semler Scientific's stock fell over 9% on the next trading day, indicating a significant market reaction to the news [5] Group 2 - Investors who suffered losses exceeding $75,000 in Semler Scientific between March 10, 2021, and April 15, 2025, are encouraged to contact the law firm to discuss their legal rights [1][7] - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995, highlighting its experience and capability in handling securities litigation [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Quantum Corporation due to alleged misleading statements and improper revenue recognition, which have resulted in significant investor losses [4][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $75,000 in Quantum Corporation between November 15, 2024, and August 18, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Quantum Corporation, with a deadline of November 3, 2025, for investors to seek the role of lead plaintiff [4]. Group 2: Financial Misconduct Allegations - The lawsuit claims that Quantum Corporation improperly recognized revenue for the fiscal year ended March 31, 2025, necessitating a restatement of previously filed financial statements for the fiscal third quarter ended December 31, 2024 [6]. - Quantum disclosed on June 30, 2025, that it would be unable to timely file its annual financial report due to a review of its accounting related to certain revenue contracts, leading to a stock price drop of $1.00, or 10.03%, closing at $8.97 per share [7]. - On August 8, 2025, Quantum announced that its third quarter 2024 financial statements should no longer be relied upon due to material weaknesses in internal controls, resulting in a revenue decrease of approximately $3.9 million and a stock price decline of $0.14, or 1.79%, to $7.66 per share [9]. - Following the announcement of the CEO's resignation on August 18, 2025, Quantum's stock price fell by $0.61, or 8.2%, closing at $6.83 per share [10].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Flywire Corporation securities during the specified Class Period of the upcoming lead plaintiff deadline on September 23, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Flywire securities between February 28, 2024, and February 25, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 23, 2025 deadline [3]. - Investors can join the class action by visiting the provided link or contacting the law firm for more information [6]. Group 2: Case Background - The lawsuit alleges that Flywire's defendants made false and misleading statements regarding the sustainability of the company's revenue growth and understated the negative impacts of permit and visa-related restrictions on its business [5]. - The lawsuit claims that these misleading statements resulted in damages to investors when the true details became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Sable Offshore Corp. securities during the specified Class Period or through the secondary public offering about the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the securities class action is defined as between May 19, 2025, and June 3, 2025, inclusive [1]. - Investors who purchased Sable securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 26, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that Sable Offshore Corp. made materially false and misleading statements regarding its oil production activities off the coast of California, claiming it had restarted production when it had not [5]. - As a result of these misleading statements, the lawsuit claims that investors suffered damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Flywire Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's revenue growth and the impact of permit and visa-related restrictions on its business [4][6]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Flywire, with a deadline of September 23, 2025, for investors to seek the role of lead plaintiff [4]. - The complaint alleges that Flywire and its executives made false and misleading statements regarding the sustainability of revenue growth and the effects of regulatory restrictions [6]. Group 2: Financial Performance and Market Reaction - On February 25, 2025, Flywire reported a net loss of $15.9 million for Q4 2024, missed consensus estimates, lowered its 2025 guidance, and announced a 10% workforce reduction [7]. - Following this announcement, Flywire's stock price dropped by $6.59 per share, or 37.4%, closing at $11.05 per share on February 26, 2025 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Semler Scientific, Inc. regarding violations of federal securities laws, particularly related to undisclosed investigations by the U.S. Department of Justice [4][6]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses in Semler Scientific to contact them to discuss their legal options [1][9]. - A federal securities class action has been filed against Semler Scientific, with a deadline of October 28, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Semler Scientific and its executives made false or misleading statements and failed to disclose a material investigation by the DOJ into violations of the False Claims Act [6][7]. Group 2: Company Financial Impact - Following the disclosure of initial settlement discussions with the DOJ, Semler Scientific's stock fell over 9% on the next trading day [7]. - The annual report filed with the SEC indicated that the company does not believe the amount of loss from potential DOJ actions can be reasonably estimated [7]. Group 3: Firm Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [5].

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Fluor Corporation (“Fluor” or the “Company”) (NYSE: FLR) between February 18, 2025 and July 31, 2025, inclusive. For more information, submit a form at Fluor Corporation Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at ...

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its product pipeline and business prospects [1][4]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to register for the class action by the deadline of September 19, 2025, to potentially be appointed as lead plaintiff [5]. Group 2: Allegations Against the Company - The complaint alleges that the product pipeline, specifically ALTO-100, was less effective in treating major depressive disorder than previously claimed, leading to overstated clinical and commercial prospects [4]. - As a result of these misleading statements, the company's business and financial outlook were also overstated, impacting the accuracy of public statements made by the company [4]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [6].

Core Viewpoint - Tronox Holdings plc (NYSE: TROX) is facing a class action lawsuit due to allegations of providing misleading statements about its financial health and sales forecasts, leading to a significant drop in stock price following disappointing financial results [1][2]. Summary by Sections Allegations - The complaint claims that Tronox made overly positive statements while concealing adverse facts about its ability to forecast demand for its products, particularly in its commercial division [1]. - Despite optimistic long-term projections, the company's forecasting processes failed, resulting in declining sales and increased costs, which ultimately affected revenue projections [1]. Financial Impact - On July 30, 2025, Tronox reported a significant reduction in TiO2 sales, attributing the decline to a weaker coatings season and increased competition [1]. - Following the announcement, Tronox lowered its full-year revenue guidance and cut its dividend by 60%, leading to a dramatic stock price drop from $5.14 to $3.19 per share, a decline of approximately 38% in one day [1]. Class Action Details - Shareholders who purchased shares during the class period from February 12, 2025, to July 30, 2025, are encouraged to register for the class action, with a lead plaintiff deadline set for November 3, 2025 [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2].